Marshall Financial Group LLC Purchases New Position in Amgen Inc. $AMGN

Marshall Financial Group LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,879 shares of the medical research company’s stock, valued at approximately $1,924,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. West Family Investments Inc. grew its stake in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after buying an additional 30 shares in the last quarter. Viawealth LLC lifted its position in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares in the last quarter. LOM Asset Management Ltd boosted its holdings in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares during the period. Sittner & Nelson LLC grew its position in Amgen by 0.4% in the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after acquiring an additional 30 shares in the last quarter. Finally, TAGStone Capital Inc. grew its position in Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent research reports. Mizuho boosted their target price on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Royal Bank Of Canada raised their price target on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. UBS Group lifted their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Wells Fargo & Company upped their price objective on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, The Goldman Sachs Group raised their target price on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Trading Down 0.6%

Shares of NASDAQ AMGN opened at $347.80 on Monday. The stock’s 50 day moving average price is $360.29 and its two-hundred day moving average price is $328.11. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The stock has a market capitalization of $187.49 billion, a P/E ratio of 24.44, a PEG ratio of 3.45 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm earned $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.